PCM
SRPT icon

Penserra Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Penserra Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,950
Closed -$940K – 1303
2024
Q2 		$940K Buy
+5,950
New +$764K 0.01% 440
2022
Q4 		– Sell
-34,123
Closed -$3.77M – 1227
2022
Q3 		$3.77M Buy
+34,123
New +$3.44M 0.11% 159

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Penserra Capital Management's SRPT Position: Q3 2024 in Review

Penserra Capital Management sold out of Sarepta Therapeutics (SRPT) in Q3 2024, closing a stake of 5,950 shares — an estimated $940K sold.

Penserra Capital Management first reported a position in SRPT in Q3 2022 and held it in 2 quarters. The position peaked at $3.77M in Q3 2022. 457 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

  • Penserra Capital Management reported no remaining Sarepta Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Penserra Capital Management sold 5,950 Sarepta Therapeutics shares in Q3 2024, an estimated $940K.
  • Penserra Capital Management first reported a position in Sarepta Therapeutics in Q3 2022 and held it in 2 quarters.
  • Penserra Capital Management's Sarepta Therapeutics position peaked at $3.77M in Q3 2022.
  • 457 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Penserra Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.